| SEGMENT INFORMATION |
NOTE
11 - SEGMENT INFORMATION
| |
|
The Company operates
as a single operating segment in the development of RNA interference (RNAi) therapies for KRAS-driven cancers. The Company’s CODM
is its Chief Executive Officer (CEO). The CODM reviews the Company’s performance on a consolidated basis. As such, the segment’s
loss is the Company’s consolidated net loss and the segment’s assets are the Company’s consolidated assets.
The CODM uses the information
primarily to evaluate the Company’s performance and allocate resources. This includes reviewing key financial metrics such as budget
versus actual expenditures, tracking progress on research and development milestones, and assessing overall cash flow and liquidity to
ensure the continuity of operations. This approach allows the CODM to monitor the Company's performance and make strategic adjustments
as needed to support its operational and financial goals.
The CODM is also regularly
provided with information on significant ordinary-course expenses, including the following expenses. The Company’s management does
not segregate the Company’s business for internal reporting. |
| |
|
Six
months ended
|
|
|
Three
months ended
June
30 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical
trials and other payments to R&D-related service providers |
|
$
|
2,429
|
|
|
$
|
598
|
|
|
$
|
1,538
|
|
|
$
|
442
|
|
|
R&D payroll
and related expenses, other than share-based compensation |
|
|
774
|
|
|
|
854
|
|
|
|
511
|
|
|
|
485
|
|
|
R&D share-based
compensation expenses |
|
|
230
|
|
|
|
-
|
|
|
|
100
|
|
|
|
-
|
|
|
G&A payroll
and related expenses, other than share-based compensation |
|
|
661
|
|
|
|
739
|
|
|
|
420
|
|
|
|
407
|
|
|
G&A share-based
compensation expenses |
|
|
312
|
|
|
|
58
|
|
|
|
97
|
|
|
|
37
|
|
|
Professional
services |
|
|
1,571
|
|
|
|
1,111
|
|
|
|
788
|
|
|
|
586
|
|
|
Depreciation
expenses |
|
|
5
|
|
|
|
7
|
|
|
|
3
|
|
|
|
3
|
|
|
Other segment
expenses (*) |
|
|
447
|
|
|
|
567
|
|
|
|
223
|
|
|
|
324
|
|
|
Operating
loss |
|
|
6,429
|
|
|
|
3,934
|
|
|
|
3,680
|
|
|
|
2,284
|
|
|
Interest
income |
|
|
(46
|
)
|
|
|
(46
|
)
|
|
|
(14
|
)
|
|
|
(44
|
)
|
|
Interest
expense |
|
|
-
|
|
|
|
11
|
|
|
|
-
|
|
|
|
-
|
|
|
Other financing
expense (income), net |
|
|
(99
|
)
|
|
|
336
|
|
|
|
(115
|
)
|
|
|
260
|
|
|
Income taxes
|
|
|
|
**
|
|
|
3
|
|
|
|
|
**
|
|
|
3
|
|
|
Net
loss |
|
|
6,284
|
|
|
|
4,238
|
|
|
|
3,551
|
|
|
|
2,503
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment assets
|
|
$
|
4,246
|
|
|
$
|
5,797
|
|
|
$
|
4,246
|
|
|
$
|
5,797
|
|
|
Expenditures
for segment assets |
|
$
|
-
|
|
|
$
|
(7
|
)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
Segment liabilities
|
|
$
|
4,202
|
|
|
$
|
5,677
|
|
|
$
|
4,202
|
|
|
$
|
5,677
|
|
| |
(*) |
Other segment expenses include mainly general
and administrative-related expenses, such as rent and maintenance expenses, travel and HR expenses. |
| |
(**) |
Represents an amount less than $1
|
|